Do Genetic Tests for DAT/NET Help Diagnose ADHD? 

Genetic tests examining DAT (dopamine transporter) and NET (norepinephrine transporter) gene variants are gaining attention in the ADHD research community, but they are not yet routine tools for ADHD diagnosis. These tests can provide insights into how dopamine and norepinephrine function in the brain, which is crucial for regulating attention, impulse control, and emotional regulation in ADHD. However, while they show promise, they are currently more useful in understanding risk factors and informing pharmacogenomics rather than directly diagnosing the condition. 

DAT and NET Gene Variants and ADHD 

The DAT and NET genes are involved in the reuptake of dopamine and norepinephrine, two neurotransmitters that are often dysregulated in ADHD. Certain gene variants in these transporters have been associated with ADHD, suggesting a genetic predisposition. For example, variations in the DAT1 gene can lead to altered dopamine reuptake, which has been linked to ADHD symptoms like impulsivity and inattention. Similarly, NET gene variants can affect norepinephrine regulation, impacting attention and emotional control. 

Genetic Testing and Pharmacogenomics 

While genetic tests for DAT and NET gene variants are not yet standard for diagnosing ADHD, they can help predict treatment response. Pharmacogenomics, the study of how genetic variations affect drug responses, can guide clinicians in choosing the most effective medications based on a patient’s genetic makeup. This is especially useful for tailoring stimulant or non-stimulant treatments for ADHD, ensuring better outcomes and fewer side effects. 

Conclusion 

Currently, DAT/NET genetic tests are not used for ADHD diagnosis, but they hold potential for understanding genetic risk factors and guiding treatment choices. Visit providers like ADHD Certify for personal consultations to explore how genetic testing can support ADHD treatment decisions and pharmacogenomics.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Dopamine and norepinephrine systems.

Victoria Rowe, MSc

Author

Victoria Rowe is a health psychologist with a Master’s in Health Psychology and a BS in Applied Psychology. She has experience as a school psychologist, conducting behavioural assessments, developing individualized education plans (IEPs), and supporting children’s mental health. Dr. Rowe has contributed to peer-reviewed research on mental health, including studies on anxiety disorders and the impact of COVID-19 on healthcare systems. Skilled in SPSS, Minitab, and academic writing, she is committed to advancing psychological knowledge and promoting well-being through evidence-based practice.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Rebecca Fernandez, MBBS

Reviewer

Dr. Rebecca Fernandez is a UK-trained physician with an MBBS and experience in general surgery, cardiology, internal medicine, gynecology, intensive care, and emergency medicine. She has managed critically ill patients, stabilised acute trauma cases, and provided comprehensive inpatient and outpatient care. In psychiatry, Dr. Fernandez has worked with psychotic, mood, anxiety, and substance use disorders, applying evidence-based approaches such as CBT, ACT, and mindfulness-based therapies. Her skills span patient assessment, treatment planning, and the integration of digital health solutions to support mental well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewer's privacy.